Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (as tocopheryl acetate) has been investigated for its potential to reduce certain side effects of chemotherapy, particularly chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common and often dose-limiting side effect of drugs such as cisplatin, paclitaxel, and oxaliplatin. Several small-scale randomized controlled trials (RCTs) and meta-analyses have evaluated Vitamin E supplementation for this purpose. Some studies suggest that Vitamin E, due to its antioxidant properties, may help protect nerve cells from oxidative damage induced by chemotherapy agents, thus reducing the incidence or severity of neuropathy.

However, the evidence is not strong or consistent. While a few studies report a modest protective effect, others show no significant benefit. Moreover, concerns have been raised that antioxidants like Vitamin E could theoretically interfere with the efficacy of chemotherapy by protecting not just healthy cells but also cancer cells from oxidative damage. No major oncology guidelines currently recommend routine Vitamin E supplementation for preventing or treating chemotherapy side effects, except possibly in the context of clinical trials. Therefore, while there is some scientific rationale and preliminary evidence, it remains inconclusive and not robust enough for routine clinical use. Patients should consult their oncologist before using Vitamin E supplements during chemotherapy.

More about Vitamin E (tocopheryl acetate)
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Vitamin E (tocopheryl acetate)

Products containing Vitamin E (tocopheryl acetate)